563 related articles for article (PubMed ID: 19502165)
1. Short-term entecavir therapy of chronic severe hepatitis B.
Chen J; Han JH; Liu C; Yu RH; Li FZ; Li QF; Gong GZ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):261-6. PubMed ID: 19502165
[TBL] [Abstract][Full Text] [Related]
2. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
4. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
Lange CM; Bojunga J; Hofmann WP; Wunder K; Mihm U; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):2001-6. PubMed ID: 19937695
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
[TBL] [Abstract][Full Text] [Related]
6. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
7. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure].
Shu X; Xu QH; Chen N; Zhang K; Li G
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):481-3. PubMed ID: 19544652
[TBL] [Abstract][Full Text] [Related]
8. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
11. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.
Yu JW; Sun LJ; Zhao YH; Li SC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1242-9. PubMed ID: 18637053
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of short-term prognosis on patients with chronic severe hepatitis B using the model for end-stage liver disease].
Zhou J; He WF; Tang XE
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):416-8. PubMed ID: 17631710
[TBL] [Abstract][Full Text] [Related]
13. [Case-controlled study of entecavir treatment for chronic severe hepatitis B].
Xiao GM; He KY; Jia WD; Lei CL; Yang Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Feb; 23(1):56-8. PubMed ID: 19799020
[TBL] [Abstract][Full Text] [Related]
14. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
15. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
16. Impact of pretransplant MELD score on posttransplant outcome in orthotopic liver transplantation for patients with acute-on-chronic hepatitis B liver failure.
Wang ZX; Yan LN; Wang WT; Xu MQ; Yang JY
Transplant Proc; 2007 Jun; 39(5):1501-4. PubMed ID: 17580172
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model.
Sun QF; Ding JG; Xu DZ; Chen YP; Hong L; Ye ZY; Zheng MH; Fu RQ; Wu JG; Du QW; Chen W; Wang XF; Sheng JF
J Viral Hepat; 2009 Jul; 16(7):464-70. PubMed ID: 19413694
[TBL] [Abstract][Full Text] [Related]
18. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.
Lai J; Yan Y; Mai L; Zheng YB; Gan WQ; Ke WM
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):154-9. PubMed ID: 23558069
[TBL] [Abstract][Full Text] [Related]
19. Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B.
Cai CJ; Chen HA; Lu MQ; Chen GH
Chin Med J (Engl); 2008 Oct; 121(20):2065-9. PubMed ID: 19080277
[TBL] [Abstract][Full Text] [Related]
20. [A study of the dosage and efficacy of entecavir for treating hepatitis B virus].
Yao GB; Zhang DF; Wang BE; Xu DZ; Zhou XQ; Lei BJ
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):484-7. PubMed ID: 16042878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
